Aligos Therapeutics (ALGS) Gains from Investment Securities (2019 - 2026)
Aligos Therapeutics (ALGS) reported Gains from Investment Securities of $58662.0 for Q1 2026, up 107.62% on a YoY basis from $28255.0 in Q1 2025, and up 1855.4% quarter-over-quarter from $3000.0 in Q4 2025.
Aligos Therapeutics (ALGS) Gains from Investment Securities (2019 - 2026) Analysis & Trends
Aligos Therapeutics has reported Gains from Investment Securities for 8 years, with the latest figure at $58662.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 107.62% year-over-year to $58662.0; the trailing twelve-month figure through Mar 2026 stood at $58662.0 (up 107.62% YoY), and the FY2025 full-year result was $1.7 million, up 175.41% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $58662.0, up from $3000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $62.1 million in Q4 2024, with the low at $3000.0 in Q4 2025.
- Historically, Gains from Investment Securities has averaged $6.2 million across 5 years, with a median of $74955.0 in 2025.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities jumped 5706.82% — and 2025, when it plunged 100.0%.
- Aligos Therapeutics' Gains from Investment Securities stood at $61000.0 in 2022, then soared by 1654.1% to $1.1 million in 2023, then jumped by 5706.82% to $62.1 million in 2024, then sank by 100.0% to $3000.0 in 2025, then jumped by 1855.4% to $58662.0 in 2026.
- The last three Gains from Investment Securities figures came in at $58662.0 (Q1 2026), $3000.0 (Q4 2025), and $74955.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Aligos Therapeutics | 54.72 Mn | -25.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58,662.00 |
| Mar 31, 2026 | 58,662.00 |
| Dec 31, 2025 | 3,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | 74,955.00 |
| Sep 30, 2025 | 74,955.00 |
| Jun 30, 2025 | 39,221.00 |
| Jun 30, 2025 | 39,221.00 |
| Mar 31, 2025 | 28,255.00 |
| Mar 31, 2025 | 28,255.00 |
| Dec 31, 2024 | 62.13 Mn |
| Dec 31, 2024 | 62.13 Mn |
| Mar 31, 2024 | 14.37 Mn |
| Mar 31, 2024 | 14.37 Mn |
| Dec 31, 2023 | 1.07 Mn |
| Dec 31, 2023 | 1.07 Mn |
| Sep 30, 2023 | 2.15 Mn |
| Sep 30, 2023 | 2.15 Mn |
| Mar 31, 2023 | 544,686.00 |
| Mar 31, 2023 | 544,686.00 |